Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 17, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than comprehensive financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. On July 13, 2007, there was an increase in the notional allocation of Ordinary Share ADRs at a price of $52.54 per share for the following individuals:
- Mrs C Bruck Slaoui (3 shares)
- Dr R G Greig (3 shares)
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a compliance notification pursuant to Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Verify the share price of $52.54 per ADR on July 13, 2007.
- Confirm the specific roles of Mrs C Bruck Slaoui and Dr R G Greig within the company.
- Review the terms of the US Retirement Savings Plan to understand the mechanics of the notional allocation.